Chenglou Zhu, Qiong Wu, Yan Xu, Jichun Ma, Yongli Hu, Junhong Wang, Zhenhua Gao, Mingxu Da
{"title":"胃癌中 N6-甲基腺苷修饰相关化疗转移酶 METTL3 的预后意义：来自荟萃分析的证据。","authors":"Chenglou Zhu, Qiong Wu, Yan Xu, Jichun Ma, Yongli Hu, Junhong Wang, Zhenhua Gao, Mingxu Da","doi":"10.1177/03936155231184908","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>N6-methyladenosine (m<sup>6</sup>A) methylation is known as the research hotspot for tumor epimodification, and its associated methyltransferase-like3 (METTL3) is significantly differentially expressed in gastric carcinoma, but its clinical value has not been summarized. This meta-analysis aimed to evaluate the prognostic significance of METTL3 in gastric carcinoma.</p><p><strong>Material and methods: </strong>Databases, including PubMed, EMBASE (Ovid platform), Science Direct, Scopus, MEDLINE, Google Scholar, Web of Science, and Cochrane Library, were used to identify relevant eligible studies. The endpoints included overall survival, progression-free survival, recurrence-free survival, post-progression survival, and disease-free survival. Hazard ratios (HR) with 95% confidence intervals (CI) were used to correlate METTL3 expression with prognosis. Subgroup and sensitivity analyses were performed.</p><p><strong>Results: </strong>Seven eligible studies involving 3034 gastric carcinoma patients were recruited for this meta-analysis. The analysis showed that high METTL3 expression was associated with significantly poorer overall survival (HR = 2.37, 95% CI 1.66-3.39, <i>P</i> < 0.01) and unfavorable disease-free survival (HR = 2.58, 95% CI 1.97-3.38, <i>P</i> < 0.01), as did unfavorable progression-free survival (HR = 1.48, 95% CI 1.19-1.84, <i>P</i> < 0.01)/recurrence-free survival (HR = 2.62, 95% CI 1.93-5.62, <i>P</i> < 0.01)/post-progression survival (HR = 1.53, 95% CI 1.22-1.91, <i>P</i> < 0.01). Subgroup analysis found that high METTL3 expression was associated with worse overall survival in patients with Chinese (HR = 2.21, 95% CI 1.48-3.29, <i>P</i> < 0.01), in studies with sample source from formalin-fixed, paraffin-embedded tissues (HR = 2.66, 95% CI 1.79-3.94, <i>P</i> < 0.01), and the reported directly from articles group (HR = 2.42, 95% CI 1.66-3.53, <i>P</i> < 0.01). The subgroup analysis that was performed based on sample size, detected method, and follow-up showed the same results.</p><p><strong>Conclusions: </strong>High expression of METTL3 predicts poor prognosis in gastric carcinoma, indicating promise for METTL3 as a prognostic biomarker.<b>Systematic review registration:</b> https://www.crd.york.ac.uk/prospero, ID = CRD42023408519.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":" ","pages":"185-193"},"PeriodicalIF":2.3000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic significance of N6-methyladenosine-modified related chemotransferase METTL3 in gastric carcinoma: Evidence from meta-analysis.\",\"authors\":\"Chenglou Zhu, Qiong Wu, Yan Xu, Jichun Ma, Yongli Hu, Junhong Wang, Zhenhua Gao, Mingxu Da\",\"doi\":\"10.1177/03936155231184908\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>N6-methyladenosine (m<sup>6</sup>A) methylation is known as the research hotspot for tumor epimodification, and its associated methyltransferase-like3 (METTL3) is significantly differentially expressed in gastric carcinoma, but its clinical value has not been summarized. This meta-analysis aimed to evaluate the prognostic significance of METTL3 in gastric carcinoma.</p><p><strong>Material and methods: </strong>Databases, including PubMed, EMBASE (Ovid platform), Science Direct, Scopus, MEDLINE, Google Scholar, Web of Science, and Cochrane Library, were used to identify relevant eligible studies. The endpoints included overall survival, progression-free survival, recurrence-free survival, post-progression survival, and disease-free survival. Hazard ratios (HR) with 95% confidence intervals (CI) were used to correlate METTL3 expression with prognosis. Subgroup and sensitivity analyses were performed.</p><p><strong>Results: </strong>Seven eligible studies involving 3034 gastric carcinoma patients were recruited for this meta-analysis. The analysis showed that high METTL3 expression was associated with significantly poorer overall survival (HR = 2.37, 95% CI 1.66-3.39, <i>P</i> < 0.01) and unfavorable disease-free survival (HR = 2.58, 95% CI 1.97-3.38, <i>P</i> < 0.01), as did unfavorable progression-free survival (HR = 1.48, 95% CI 1.19-1.84, <i>P</i> < 0.01)/recurrence-free survival (HR = 2.62, 95% CI 1.93-5.62, <i>P</i> < 0.01)/post-progression survival (HR = 1.53, 95% CI 1.22-1.91, <i>P</i> < 0.01). Subgroup analysis found that high METTL3 expression was associated with worse overall survival in patients with Chinese (HR = 2.21, 95% CI 1.48-3.29, <i>P</i> < 0.01), in studies with sample source from formalin-fixed, paraffin-embedded tissues (HR = 2.66, 95% CI 1.79-3.94, <i>P</i> < 0.01), and the reported directly from articles group (HR = 2.42, 95% CI 1.66-3.53, <i>P</i> < 0.01). The subgroup analysis that was performed based on sample size, detected method, and follow-up showed the same results.</p><p><strong>Conclusions: </strong>High expression of METTL3 predicts poor prognosis in gastric carcinoma, indicating promise for METTL3 as a prognostic biomarker.<b>Systematic review registration:</b> https://www.crd.york.ac.uk/prospero, ID = CRD42023408519.</p>\",\"PeriodicalId\":50334,\"journal\":{\"name\":\"International Journal of Biological Markers\",\"volume\":\" \",\"pages\":\"185-193\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Biological Markers\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/03936155231184908\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/7/2 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Biological Markers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03936155231184908","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：N6-甲基腺苷（m6A）甲基化被称为肿瘤表修饰的研究热点，与之相关的甲基转移酶样3（METTL3）在胃癌中显著差异表达，但其临床价值尚未被总结。这项荟萃分析旨在评估METTL3在胃癌中的预后意义：使用PubMed、EMBASE（Ovid平台）、Science Direct、Scopus、MEDLINE、Google Scholar、Web of Science和Cochrane Library等数据库来确定符合条件的相关研究。研究终点包括总生存期、无进展生存期、无复发生存期、进展后生存期和无病生存期。用危险比（HR）和95%置信区间（CI）将METTL3的表达与预后相关联。进行了亚组分析和敏感性分析：本次荟萃分析共收集了 7 项符合条件的研究，涉及 3034 名胃癌患者。分析表明，METTL3的高表达与总生存率明显较低有关（HR = 2.37，95% CI 1.66-3.39，P P P P P P P P P结论：METTL3的高表达可预测胃癌的预后：METTL3的高表达可预测胃癌的不良预后，表明METTL3有望成为一种预后生物标志物。系统综述注册：https://www.crd.york.ac.uk/prospero，ID = CRD42023408519。
Prognostic significance of N6-methyladenosine-modified related chemotransferase METTL3 in gastric carcinoma: Evidence from meta-analysis.
Background: N6-methyladenosine (m6A) methylation is known as the research hotspot for tumor epimodification, and its associated methyltransferase-like3 (METTL3) is significantly differentially expressed in gastric carcinoma, but its clinical value has not been summarized. This meta-analysis aimed to evaluate the prognostic significance of METTL3 in gastric carcinoma.
Material and methods: Databases, including PubMed, EMBASE (Ovid platform), Science Direct, Scopus, MEDLINE, Google Scholar, Web of Science, and Cochrane Library, were used to identify relevant eligible studies. The endpoints included overall survival, progression-free survival, recurrence-free survival, post-progression survival, and disease-free survival. Hazard ratios (HR) with 95% confidence intervals (CI) were used to correlate METTL3 expression with prognosis. Subgroup and sensitivity analyses were performed.
Results: Seven eligible studies involving 3034 gastric carcinoma patients were recruited for this meta-analysis. The analysis showed that high METTL3 expression was associated with significantly poorer overall survival (HR = 2.37, 95% CI 1.66-3.39, P < 0.01) and unfavorable disease-free survival (HR = 2.58, 95% CI 1.97-3.38, P < 0.01), as did unfavorable progression-free survival (HR = 1.48, 95% CI 1.19-1.84, P < 0.01)/recurrence-free survival (HR = 2.62, 95% CI 1.93-5.62, P < 0.01)/post-progression survival (HR = 1.53, 95% CI 1.22-1.91, P < 0.01). Subgroup analysis found that high METTL3 expression was associated with worse overall survival in patients with Chinese (HR = 2.21, 95% CI 1.48-3.29, P < 0.01), in studies with sample source from formalin-fixed, paraffin-embedded tissues (HR = 2.66, 95% CI 1.79-3.94, P < 0.01), and the reported directly from articles group (HR = 2.42, 95% CI 1.66-3.53, P < 0.01). The subgroup analysis that was performed based on sample size, detected method, and follow-up showed the same results.
Conclusions: High expression of METTL3 predicts poor prognosis in gastric carcinoma, indicating promise for METTL3 as a prognostic biomarker.Systematic review registration: https://www.crd.york.ac.uk/prospero, ID = CRD42023408519.
期刊介绍：
IJBM is an international, online only, peer-reviewed Journal, which publishes original research and critical reviews primarily focused on cancer biomarkers. IJBM targets advanced topics regarding the application of biomarkers in oncology and is dedicated to solid tumors in adult subjects. The clinical scenarios of interests are screening and early diagnosis of cancer, prognostic assessment, prediction of the response to and monitoring of treatment.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
